45 results about "Synovial joint" patented technology

A surgical implant for replacing hyaline cartilage in a knee or other articulating synovial joint has an anchoring side on one side of the implant adapted for fixing the implant to one of the bones in the joint, and a bearing surface on the opposite side of the implant for lubricious rubbing and sliding contact with another bone in the joint. The anchoring side can be configured with an irregular surface for tissue ingrowth. The bearing side can include hydrogel. The implant can be rolled up from an original shape and surgically inserted by arthroscopic means, and opens into its original shape when released inside the joint.

A method of intra-articular drug delivery may include selecting an attachment zone in a synovial joint; affixing a drug release device in the attachment zone, the drug release device comprising a base affixable in the attachment zone, a sustained-release drug carrier, and a drug, the device positioned so that the device releases the drug into the synovial fluid of the synovial joint, and so that agitation of the synovial fluid facilitates elution of the drug from the drug release device.

Methods and apparatus for immobilizing a synovial joint, such as a sacroiliac (SI) joint are disclosed. In one form, a multipiece fixation device, such as a dowel, includes multiple expandable fasteners that are configured to fix adjacent bones of a synovial joint with respect to one another. The expandable fasteners include expansion portions that are expanded radially via insertion of another expandable fastener or an expansion device to fix the expandable fasteners to the bone. The fixation device may be configured to provide for compression or distraction of the bones of the synovial joint while at the same time stabilizing the joint.

A method of intra-articular drug delivery may include selecting an attachment zone in a synovial joint; affixing a drug release device in the attachment zone, the drug release device comprising a base affixable in the attachment zone, a sustained-release drug carrier, and a drug, the device positioned so that the device releases the drug into the synovial fluid of the synovial joint, and so that agitation of the synovial fluid facilitates elution of the drug from the drug release device.

An antibiotic delivery system including an intramedullary stem that is adapted to be removably mounted into a medullary canal of a bone. The stem includes a body having an inlet adapted to be in fluid communication with a source of liquid-borne antibiotic and a plurality of outlets disposed along the stem. A channel extends between the inlet and the plurality of outlets for delivering a fluid-borne antibiotic from the inlet to the plurality of outlets so as to distribute the antibiotic along the medullary canal in a controlled fashion. A method of treating an infected joint during a two-stage re-implantation of an orthopedic implant is also disclosed.

A synovial joint implantable apparatus for the reconstruction of skeletal defects with a flexible member, which is preferably resorbable, attached to a rigid structural prosthesis such as a total hip or total knee replacement implant. The cavitary space defined and surrounded by the flexible member is filled with osteoconductive and / or inductive materials which eventually matures into new column of bone. The prosthesis is supported by the bed of graft material surrounding it and is gradually unloaded as the bed matures into solid bone. The fixation of the prosthesis into native bone depends on the specific implant and the anatomic area of its use. The flexible member is secured to the margins of the prosthesis using rails, runners, sutures, or other attachment devices that prevent the escape of the bone graft and maintain an initial column of support for the implant. Should the metal implant even need removal, the reconstituted bone can be separated from the implant in such a way as to restore bone stock and facilitate future revision surgical procedures.

Methods and apparatus of providing a subject with post-operative, sustained-release of a biological agent within a synovial joint is disclosed. These methods involve securing a depot containing the biological agent to a ligament, tendon, muscle within the joint to provide sustained-release of the agent while allowing for normal joint articulation. This methodology may be utilized to provide for sustained-release of a biological agent useful in treating various traumas and disorders of the joint. Such biological agents include antagonists of inflammation-related proteins, such as TNF-α, IL-1β, IL-6, IL-8, NF-κB, High Mobility Group Box 1 (HMG-B1), IL-2, IL-15 and steroidal and non-steroidal anti-inflammatories. Other biological agents include anti-inflammatory cytokines such as IL-10, IL-4, IL-13, and TGF-β. The biological agents also include osteogenic and cartilage producing growth factors such as, but not limited to, BMP-2, BMP-4, BMP-6, BMP-7, BMP-8, and MIA CD-RAP. Finally, the biological agents include siRNA and / or therapeutic antibodies.

Recombinant lubricin molecules and uses thereof. Novel recombinant lubricin molecules and their uses as lubricants anti-adhesive agents and / or intra-articular supplements for, e.g., synovial joints, meniscus, tendon, peritoneum, pericardium and pleura are provided.

Methods and apparatus for immobilizing a synovial joint, such as a sacroiliac (SI) joint are disclosed. In one form, a multipiece fixation device, such as a dowel, includes multiple expandable fasteners that are configured to fix adjacent bones of a synovial joint with respect to one another. The expandable fasteners include expansion portions that are expanded radially via insertion of another expandable fastener or an expansion device to fix the expandable fasteners to the bone. The fixation device may be configured to provide for compression or distraction of the bones of the synovial joint while at the same time stabilizing the joint.

Methods and compositions are disclosed for an intra-articular injection for the treatment of osteoarthritis. The methods and compositions comprising combinations of hyaluronic acid and a bone morphogenetic protein, like rhGDF-5, can be useful for any synovial joint, including the knee, shoulder, hip, ankle, hands, spinal facet, or temporomandibular joint, both for the relief of pain and for slowing disease progression.

A method of intra-articular drug delivery may include selecting an attachment zone in a synovial joint; affixing a drug release device in the attachment zone, the drug release device comprising a base affixable in the attachment zone, a sustained-release drug carrier, and a drug, the device positioned so that the device releases the drug into the synovial fluid of the synovial joint, and so that agitation of the synovial fluid facilitates elution of the drug from the drug release device.

A synovial joint implantable apparatus for the reconstruction of skeletal defects with a flexible member, which is preferably resorbable, attached to a rigid structural prosthesis such as a total hip or total knee replacement implant. The cavitary space defined and surrounded by the flexible member is filled with osteoconductive and / or inductive materials which eventually matures into new column of bone. The prosthesis is supported by the bed of graft material surrounding it and is gradually unloaded as the bed matures into solid bone. The fixation of the prosthesis into native bone depends on the specific implant and the anatomic area of its use. The flexible member is secured to the margins of the prosthesis using rails, runners, sutures, or other attachment devices that prevent the escape of the bone graft and maintain an initial column of support for the implant. Should the metal implant even need removal, the reconstituted bone can be separated from the implant in such a way as to restore bone stock and facilitate future revision surgical procedures.

Methods and compositions are disclosed for an intra-articular injection for the treatment of osteoarthritis. The methods and compositions comprising combinations of hyaluronic acid and a bone morphogenetic protein, like rhGDF-5, can be useful for any synovial joint, including the knee, shoulder, hip, ankle, hands, spinal facet, or temporomandibular joint, both for the relief of pain and for slowing disease progression.

A composite tissue formed in situ is provided. The composite tissue includes a synovial joint tissue; and a barrier material adhered thereto for sealing the synovial joint tissue against synovial fluid. Also provided is a method for regenerating synovial joint tissue in situ by excluding synovial fluid therefrom. The method includes providing a synovial joint tissue having a defect; and placing a barrier material in intimate contact with the defect for sealing the defect against synovial fluid. The barrier material includes a curable protein copolymer. The method further includes curing the protein copolymer in situ. The barrier material can include a crosslinked network, or a self gelled network of repeating elastin-like and fibroin-like polymer chains.

A method of treating a synovial joint by injecting particles of collagen-based material into the joint. The particles may be dehydrated before implantation, and rehydrated after implantation, or they may be implanted in a “wet” state—such as a slurry or gel. Radiocontrast materials may be included to enhance imaging of the injected material. Other additives may include analgesics, antibiotics, proteoglycans, growth factors, and / or other cells effective to promote healing and / or proper joint function.

Systems and methods for purification and concentration of autologous alpha-2-macroglobulin (A2M) from whole blood are provided. Also provided are diagnostic methods for identifying sites in the synovial joints, spine, tendons or ligaments for treatment of pain, degeneration, or inflammation with autologous A2M. Methods for utilizing autologous A2M in combination with other autologous treatments (e.g. platelets and other growth factors) are provided in addition to combinations with exogenous drugs or carriers. Also provided is a method of producing recombinant A2M wild type or variants thereof where the bait region was modified to enhance the inhibition characteristics of A2M and / or to prolong the half life of the protein in joints and spine disc or epidural space.

Disclosed are methods of treating inflammation within a synovial joint, comprising administering to the joint a composition comprising primed stem or progenitor cells in an amount effective to enhance recovery, and a pharmaceutically acceptable carrier.